Navigation Links
How 'phenotype switching' can make melanoma become metastatic and resistant to drugs
Date:10/19/2013

BRAF cell lines to determine their Wnt5A and ROR2 status, as well as their sensitivity to BRAF inhibitors, the researchers found a significant correlation between BRAF inhibitor resistance and Wnt5A expression. Additionally, in a small cohort of patients, they found that seven out of nine patients who demonstrated less than a 33 percent clinical response to vemurafenib had a positive expression of Wnt5A, and only two of the remaining 15 patients who had a 38% or greater clinical response to vemurafenib exhibited any Wnt5A expression. When they silenced ROR2 in tumors xenografted in mice, the tumors responded far better to simultaneous treatment with the BRAF inhibitor vemurafenib. Conversely, when ROR1 was silenced, the tumors became more resistant to the drug.

Additionally, in eight patients who had undergone BRAF inhibitor therapy, the levels of Wnt5A were much lower in tumor cells prior to therapy compared to cells that were tested for Wnt5A after those same patients had relapsed.

"By using Wnt5A as a biomarker, we could determine which patients are likely to respond better to therapy with vemurafenib and help prolong that response," Weeraratna said. "There is also the potential to explore small molecule inhibitors of ROR2, since there is now a clear association between that and the ability of melanoma to become not only metastatic, but also therapy-resistant. This link between metastasis and therapy resistance is what we find the most exciting and intriguing, as therapies designed to target one process may have a significant impact on the other as well. "


'/>"/>

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. $1.5 million NCI Grant to aid Huntsman Cancer Institute researcher study melanoma, sun damage link
2. University of Houston engineering professor awarded grant to study melanoma treatment
3. AACR news: New target plus new drug equals death of melanoma cells
4. Gene mutation immortalizes malignant melanoma
5. Gene in eye melanomas linked to good prognosis
6. Serendipity points to new potential target and therapy for melanoma
7. Better approach to treating deadly melanoma identified by scientists
8. Fighting melanomas attraction to the brain
9. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
10. New line of approach for combination therapy against melanoma
11. Why tumors become drug-resistant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Bethesda, MD This FASEB Science Research Conference brings ... define how the conformations of cellular proteins are achieved ... aberrant protein conformations arise. Specific sessions ... pathways, the mechanisms of action of molecular chaperones, pathways ...
... JUPITER, FL, January 22, 2013 How aging affects ... that makes it more difficult to treat a range ... A new study from the Florida campus of The ... affects the brain,s neural circuitry, in some cases significantly ...
... accurate information about endangered bats, birds and insects. A new ... revealed many previously unknown and highly valuable details about bats. ... in tents for several days with binoculars and infrared cameras ... system, which for two months has continuously recorded bat activity ...
Cached Biology News:Scripps Florida scientists offer new insight into neuron changes brought about by aging 2New monitoring technique reveals endangered animals 2New monitoring technique reveals endangered animals 3
(Date:4/21/2015)... Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: ... elected Rene-Pierre Azria as a Director and ... oversight on strategic and financial transactions. Mr. Azria will ... Compensation Committee and the Corporate Governance and Nomination Committee. ... have a long-time interest in Life Sciences and in ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or "Novogen"), ... entered into definitive agreements today to issue approximately ... 6-month option and half of one attaching 5-year ... investors in the United States ... proceeds of approximately AU$15,500,000 ("Placement"). The closing of ...
(Date:4/21/2015)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before market open on Tuesday, April 28, ... teleconference on Tuesday, April 28, 2015, at 9:00 a.m. ... with international callers dialing 1-970-315-0533.  A rebroadcast of the ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6
... , , MENLO ... California-based partners hosted the California Bioscience Business Roundtable (BBR) event at ... featured Sam Youngman, the White Correspondent for The Hill newspaper, who ... debate in Washington, D.C. , , Bioscience represents ...
... , , The statement below is from Pete ... Company, its employees and its Board of Directors. , , ... across a remarkably broad spectrum of issues. Foremost among them was his ... , , He was a tireless advocate for patients, rights ...
... 11%, - Strong Research and Investment Effort, - Positive net Financial Position, - Annual ... Saporta approved the 2009 half year financial statements: , , In million Euros ... ... Sales 87.0 ...
Cached Biology Technology:California Life Science, Business, and Economic Development Experts Discuss California's Bioscience Future 2Boston Scientific Statement on the Passing of Senator Edward Kennedy 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
Biology Products: